Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Owkin and Sanofi SA (NASDAQ: SNY ) on Friday announced they have expanded their partnership through a new multi-year collaboration focused on developing next-generation AI-powered biopharma agents to support drug discovery and development. The agreement also includes a five-year license for Owkin's AI Scientist platform, K Pro, marking the latest phase in a relationship that began in 2021. Partnership Builds On Existing AI Research Efforts The companies first teamed up through a 90 million euro strategic partnership centered on oncology target identification and patient subgroup analysis. data-variant="card" data-news-mode="manual" > Read Also: Microsoft Bets Big On Healthcare AI, Teams Up With Mayo Clinic The collaboration was later broadened to support drug positioning efforts within Sanofi's immunology pipeline. The newly announced initiative represents a deeper integration of AI into pharmaceutical ... Full story available on Benzinga.com